

Vincenzo Sforza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1354679/publications.pdf>

Version: 2024-02-01

22
papers

1,311
citations

623574

14
h-index

713332

21
g-index

22
all docs

22
docs citations

22
times ranked

2577
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of gastric cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 1635.	1.4	508
2	Increased TGF- β as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR-MET Interaction and Activation of MET Signaling in Colon Cancer Cells. <i>Clinical Cancer Research</i> , 2013, 19, 6751-6765.	3.2	130
3	Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 6345.	1.4	94
4	Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. <i>World Journal of Gastroenterology</i> , 2017, 23, 4675.	1.4	91
5	Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. <i>Clinical Cancer Research</i> , 2014, 20, 3775-3786.	3.2	89
6	Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. <i>International Journal of Cancer</i> , 2013, 133, 2089-2101.	2.3	81
7	EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 845-855.	1.9	58
8	Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. <i>Oncologist</i> , 2018, 23, 1178-1187.	1.9	46
9	Clinical management of advanced gastric cancer: The role of new molecular drugs. <i>World Journal of Gastroenterology</i> , 2014, 20, 14537.	1.4	41
10	RET Inhibitors in Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 4415.	1.7	34
11	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. <i>ESMO Open</i> , 2018, 3, e000299.	2.0	29
12	Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. <i>ESMO Open</i> , 2017, 2, e000177.	2.0	27
13	Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer. <i>Oncotarget</i> , 2017, 8, 68305-68316.	0.8	27
14	Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation. <i>Oncotarget</i> , 2017, 8, 67592-67604.	0.8	15
15	Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme. <i>ESMO Open</i> , 2017, 2, e000229.	2.0	14
16	Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?. <i>Therapeutic Advances in Medical Oncology</i> , 2013, 5, 51-72.	1.4	11
17	Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer. <i>ESMO Open</i> , 2019, 4, e000519.	2.0	5
18	Pembrolizumab in lung cancer: current evidence and future perspectives. <i>Future Oncology</i> , 2019, 15, 3327-3336.	1.1	4

#	ARTICLE	IF	CITATIONS
19	The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung cancer. Expert Opinion on Drug Safety, 2020, 19, 775-783.	1.0	2
20	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. Journal of Clinical Oncology, 2015, 33, TPS3634-TPS3634.	0.8	2
21	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. Journal of Clinical Oncology, 2015, 33, TPS789-TPS789.	0.8	2
22	Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer. , 2020, 1, 117-130.		1